The CCO provided a high-level overview on several areas including the following.
The CCO started with a brief update on Covid figures and boosters. In the 7 days up to 2nd March there were 22,990 new cases reported (based on positive PCR results); down 21% on the previous week (28,979 new cases in the 7 days up to 23rd February). There have been 2,817,835 booster vaccines administered, 2,681,261 additional dose vaccines and 136,574 immunocompromised dose vaccines administered. Plans are being currently being reviewed in relation to the vaccination programme which will be completed in March.
Significant progress has been made by the COVID-19 Therapeutics Implementation Working Group to support the roll out of Covid-19 therapeutics recommended by the Covid-19 Therapeutics Advisory Group. Since the previous update to the Board, the Working Group has worked with Hospitals to coordinate stock control of the supplies of Covid-19 therapeutics and monitor the numbers of doses being administered weekly. Based on the advice of the Therapeutic Advisory Group and other information it was clear that the priority for patient safety was to deliver access to this agent as quickly as possible to those patients at greatest risk of severe disease.
At the last meeting the report from the National Screening Programme articulated a risk in relation to the ability to recruit consultant radiologists for BreastCheck. The CCO has requested NSS to establish a working group with representatives from the faculty, symptomatic services and breastcheck. The aim of this group is to explore short, medium and long term options, look at training positions, education, and the promotion of breast radiology as a career option. In the immediate term, BreastCheck continue to actively recruit and aim to appoint consultants into vacancies across all four units. They are also seeking additional capacity from both existing BreastCheck consultants and consultants working in symptomatic services within the bounds of the existing pay policy whilst recognising competing pressures across the health system and very competitive market. CCO to supply a report on staffing required for Screening for next meeting.
Significant progress has been made in implementing the recommendations of Dr Scally’s Scoping Inquiry into the CervicalCheck screening programme. The latest quarterly progress report was published on the 3rd of March 2022 and shows that just four of 170 actions, arising from Dr Scally’s recommendations, remained to be completed at end 2021. The Minister for Health has requested Dr Gabriel Scally to conduct a final progress review of implementation of his recommendations, and this work is now underway
Cancer services are currently operating near full capacity, with some ongoing local difficulties related to staffing absences and acute capacity issues. Ongoing access to private services remains essential and this need is likely to continue for some time, particularly in clearing backlogs for non-complex cancer care and ensuring timely cancer treatment. Staffing, recruitment and retention in cancer services continue to be a challenge.
At the last Safety and Quality meeting it was agreed that the 6-month report on the OEST programme would be shared with the committee. OEST are moving to the next stage of the programme with involvement of all 19 maternity units from the 1st of April. At the last meeting a question was raised if the number of events which have been captured were expected. There were three maternal deaths, seven hypoxic-ischemic encephalopathy (HIE) and two Intrapartum deaths. Maternal death appears to be overrepresented, but they still remain a small number, and are potentially a statistical artefact, with an annual expectation of 5 – 7 for the whole country in a full year. As a result of these cases NWIHP issued a system notification to ensure that there was heightened awareness of these events. As the programme gains momentum within the system, it is anticipated that there will be increased engagement with the OEST and a rise in the number of cases reported. The OEST has designated four events that need particular attention, these are: a) Maternal death b) Intrapartum fetal death c) Early neonatal death d) Babies requiring therapeutic hypothermia B, c and d above apply to term babies with no life limiting conditions (as these conditions would have been known beforehand). These are the criteria outlined by the RCOG for Each Baby Counts since 2015.
Current HSE records indicate that there is a total of 747 nurses/midwives employed in CNS/CMS in the community (however a number of these post holders may be working as CNM2’s). At the last safety and quality meeting last month there was a request to understand the breakdown of CNS/CMS specialist posts by geographical area this report will be shared at the next SQ meeting.
In November 2021, the Minister for Health asked that the number of ANMPs in the health service be increased from 2% to 3% of the workforce. The total nursing and midwifery workforce in the public system was 41,136 WTE (November 2021). At this time the total number of Advanced Nurse and Midwife Practitioners (ANMPs) was 733 WTE (1.75%) including 553 WTE Registered ANMP posts and 180 WTE candidate ANMP posts. These posts should have a renewed focus on the objectives of Sláintecare and the HSE corporate objectives. There is an opportunity now to harness these advanced practice roles to support patients in the community and hospitals in managing integrated care. The DOH Letter of determination to the HSE set out a funding of 11.9milliom as part of the HSE National Service Plan 2022 new development initiative to expand the number of ANMPs in 2022 service. It is accepted that €1m will be required to support the education of candidate posts and there will be 164 WTE posts available. As a next step a paper is being developed to outline a governance structure to provide a strategic direction for these posts that will ensure that their future development aligns to with both the HSE and Sláintecare objectives.
The CCO provided the Committee with an update on Letterkenny University Hospital. The Price review was published by the SAOLTA Healthcare Group in August 2020. This review made 6 key recommendations and the SAOLTA group developed an action plan for their implementation. To date over 85% of the recommendations are complete and the remaining recommendations are being progressed. The CCO informed the Committee that he has requested the Clinical Director of NWIHP to meet with the Director of Women's and Children's Managed Clinical and Academic Network and arrange to meet clinicians in Letterkenny University Hospital in relation to the service and reported incidents. CCO has asked for an assessment and advice including any observations in relation to safety in the gynaecological department and any recommendations if necessary, to make it safer, bearing in mind any existing concerns emanating from reports in relation to the service.
The original guideline on PMB (2013, revised 2016) suggested that these women should be seen in a short timeframe. Interim guidance with specific timeframes was issued by the Acute Hospital Division August 2020. Now that we have specific timeframes the hospital groups are being asked to measure their performance against these specific timeframes. This is the first KPI in general gynaecology. A formal guideline has been commissioned which will be available later this year, it is anticipated that the principles in this guidance will be the same and the timeframe is unlikely to differ substantially. As part of the process of developing clinical guidance it is important that the most up to date evidence and research is reviewed. The guideline in addition to international evidence is reviewed under the clinical leadership of the NWIHP in the context of an Irish Health Care System and will be peer reviewed through the normal clinical governance structures set up by CCO. This process aims to ensure that clinical guidance development is transferable to clinical practice, aligned and integrated across the healthcare system, and there is clear clinical governance and oversight.
Although clinical genetics is an established medical sub-specialty and there are some pockets of excellence in the country, Ireland lags considerably behind other countries in harnessing the power of genomic data and research to inform clinical decision making. There is now a large and increasing disparity between services offered in Ireland and international best practice. As a result, very few Irish patients are benefitting from advances in genomics and the gap is widening. Compared to other European countries, Medical Genetics in Ireland is under-resourced for both clinical and laboratory services. At present, the average waiting time for a routine genetics appointment is 2 years. Due to the lack of a genomic infrastructure, a significant volume of patient samples is sent overseas for testing leading to increased costs. In addition, tests that are carried out in-house have a higher unit cost compared to other 9 laboratories carrying out similar genetic testing. There is a shortage of trained genetic specialists, substantial knowledge gaps in the clinical workforce and a lack of genetic/genomic literacy across healthcare professionals and the public. Appropriate governance structures, policies, procedure, and protocols are not in place and Ireland has no strategy or funding in place to develop a genomic service to improve health outcomes, drive down the cost of care and fuel scientific innovation and discovery. There have been several reports published to date with recommendations for a national strategy and plan to develop and strengthen the genomics service. Following recommendations from this, the government committed to establishing a National Genetics and Genomic Medicine Network (NGGMN). The NGGMN aims to facilitate the development of a nationally coordinated service for genetics and genomics. Recruitment for a National Genetics and Genomics Medicine lead was first advertised in February 2020 and following a global, competitive, and open recruitment process a world leading expert in genomics was offered the position of Director of the NGGMN in January 2021, but the position was not taken up due to lack of multi annual budget for the service. The Committee were very disappointed to hear that the position is still vacant due to a lack of funding and felt a position should not be recruited if the funding is not available to run the service. A business case for genomic funding was submitted by the office of the CCO in September 2021. However, funding under the National Service Plan was not secured. The priority now is to support the progression of a Genetics and Genomics strategy with a single vision for the future of genetics and genomics. Genomics is now revolutionising how we deliver healthcare.
The Committee were given a brief update on Navan hospital, which is the last hospital to be brought back to a Model 2 hospital. CCO expressed concerns that this hospital cannot provide proper care and is a patient safety concern. Whilst the issue was brought to the attention of the Minister, there did not seem to be a sense of urgency about the actions needed. CCO advised that the next step is to write to the hospital and the Department, advising that the changes will be actioned, giving 4 weeks’ notice of the change. The Committee were in agreeance that the Committee Chair would write to the Board Chair advising of the next steps needed and the urgency of this matter. The Committee were united in their dissatisfaction with the situation and the delay in these important changes being made and strongly support the CCO’s plan of action.
The Open Disclosure Annual Report has been reviewed and approved by the EMT for further presentation to the Safety and Quality Committee. The Annual Report provides an overview of the work of the office in relation to the office functions. The report provides an overview of the following; The Mission, Vision and Values of the National Open Disclosure Office, Key Developments in Open Disclosure during 2020, Managing the impact of the Coronavirus Pandemic and Covid-19 Restrictions on the work of the National Open Disclosure Office and Programme throughout 2020, An Update on the Operations Plan for the National Open Disclosure Office 2020, Update on the Implementation of the Recommendations from the report by Dr Gabriel Scally into CervicalCheck 2018, Update on the National Open Disclosure Training and Education Programme including a training report for 2020, Programme of work undertaken to improve the access to and uptake of open disclosure training by Medical Staff, Governance, Performance Measurement, Partnering with Patients and Service Users, Stakeholder Involvement, Sharing the Learning – case examples